- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00956722
Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy
This is an exploratory trial of Bovine Colostrum powder to decrease translocation of gut-derived microbial products and immune activation in HCV infection.
The study is designed as a single-arm, open-label, before-and after exploratory trial of 10 weeks of Bovine Colostrum Powder (BCP) to reduce translocation of intestinal microbial products and immune activation in patients suffering from chronic hepatitis C virus (HCV) infection.
The study population will include HCV-infected (genotype 1) men and women, ≥ 18 years of age, not receiving anti-viral therapy at the time of enrollment and for at least the previous 3 months. Having failed previous anti-viral therapy (non responders), HCV recurrence after 72 weeks of therapy, developed side effects which mandated stopping anti viral therapy, or not considered eligible for initiation of such treatment, with a plasma HCV RNA level ≥ 1000 I.U.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Liver Unit, Hadassah Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic HCV infection (genotype 1), as documented by a positive anti HCV titer, and confirmed by positive HCV RNA.
- Non responder to previous antiviral therapy, HCV recurrence after 72 weeks of therapy, previous antiviral therapy stopped due to side effects, or not a candidate for treatment with interferon + ribavirin.
- No antiviral therapy for at least 3 months.
- HCV RNA ≥1,000 IU obtained within 30 days prior to study entry.
- Not currently listed for liver transplantation
- Female study subjects of reproductive potential (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure (hysterectomy or bilateral oophorectomy) must have a negative serum or urine pregnancy test performed within 48 hours before initiating the protocol-specified medication(s) unless otherwise specified by product labeling.
- All study subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
If participating in sexual activity that could lead to pregnancy, the study volunteer must agree that two reliable methods of contraception will be used simultaneously while receiving the protocol-specified medication and for 1 month after stopping the medication. NOTE: Hormonal-based methods alone are not sufficient. At least two of the following methods MUST be used appropriately unless documentation of menopause, sterilization, or azoospermia is present:
- Condoms (male or female) with or without a spermicidal agent. Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission;
- Diaphragm or cervical cap with spermicide;
- IUD;
- Hormonal-based contraception.
Study subjects who are not of reproductive potential (girls who have not reached menarche or women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy and/or bilateral oophorectomy are eligible without requiring the use of contraceptives. Written or oral documentation communicated by clinician or clinician's staff is required by one of the following:
- Physician report/letter;
- Operative report or other source documentation in the patient record (a laboratory report of azoospermia is required to document successful vasectomy);
- Discharge summary;
- Laboratory report of azoospermia;
- FSH measurement elevated into the menopausal range as established by the reporting laboratory.
- Men and women age > 18 years.
- Ability and willingness of subject or legal guardian/representative to provide informed consent.
Exclusion Criteria:
- Pregnancy or Breast-Feeding
Continuous use of the following medications for more than 3 days within 30 days of study entry:
- Immunosuppressives;
- Immune modulators;
- Systemic glucocorticoids;
- Anti-neoplastic agents;
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
Active treatment with Bovine colostrum
|
Bovine Colostrum Powder (Biogard)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine if the administration of BCP will reduce the levels of intestinal microbial products in the bloodstream of HCV-infected, untreated persons.
Time Frame: 10 weeks
|
10 weeks
|
To determine the safety of the administration of oral BCP to patients with chronic HCV
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine whether the administration of BCP will reduce HCV RNA levels or the frequency of T cells expressing markers of cellular immune activation in the peripheral blood of HCV-infected, untreated persons.
Time Frame: 10 weeks
|
10 weeks
|
To determine whether the changes in levels of intestinal microbial products in plasma after administration of BCP are associated with changes in HCV RNA levels or the frequency of activated T cells in the peripheral blood
Time Frame: 10 weeks
|
10 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Immuron Travelan HCV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asymptomatic Chronic HCV Carriers
-
Gilead SciencesCompletedChronic Genotype 4 HCV | Chronic Genotype 5 HCVFrance
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.Recruiting
-
Gilead SciencesCompletedChronic HCV InfectionBelgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
-
Gilead SciencesCompletedChronic HCV InfectionChina, Hong Kong, Taiwan, Korea, Republic of, Vietnam
-
Gilead SciencesCompletedChronic HCV InfectionUnited States
-
Gilead SciencesCompletedChronic HCV InfectionChina, Korea, Republic of, Taiwan
-
Gilead SciencesCompleted
-
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Peking University People's HospitalCompletedCirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïveChina
Clinical Trials on Bovine Colostrum Powder
-
Centro de Investigación en Alimentación y Desarrollo...Completed
-
Hadassah Medical OrganizationCompletedNonalcoholic Steatohepatitis | Fatty Liver DiseaseIsrael
-
National Nutrition and Food Technology InstituteCompletedCritical IllnessIran, Islamic Republic of
-
Immuron Ltd.WithdrawnNonalcoholic Steatohepatitis
-
Ain Shams UniversityCompletedFeeding; Difficult, Newborn | Necrotizing Enterocolitis of Newborn | Late Onset Neonatal SepsisEgypt
-
Milky Way Life Sciences LLCBeth Israel Deaconess Medical CenterRecruitingCeliac Disease | Gluten Sensitivity | Non-celiac Gluten SensitivityUnited States
-
Assiut UniversityNot yet recruiting
-
National Nutrition and Food Technology InstituteCompletedCritical Illness | Multiple Organ Dysfunction Syndrome | Infection ComplicationIran, Islamic Republic of
-
Virginia Commonwealth UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Immuron Ltd.CompletedHepatitis, AlcoholicUnited States
-
University of MessinaUniversity of Victoria; University of AthensCompletedMenopause | Vulvovaginal Atrophy